A health condition index for assessing disease progression.

Introduction: Currently immunotherapy is considered a cutting edge pharmaceutical treatment for non-small cell lung cancer. Tumor profile plays a crucial role in identifying the correct patient group.

Methods: Therefore, initial biopsies and re-biopsies are necessary in order to identify the expression of programmed death-ligand-1.